Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens

The enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistan...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2020-03, Vol.64 (4)
Main Authors: Biagi, M, Shajee, A, Vialichka, A, Jurkovic, M, Tan, X, Wenzler, E
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Azabicyclo Compounds - pharmacology
Bacterial Proteins - genetics
beta-Lactamase Inhibitors - pharmacology
beta-Lactamases - genetics
Boronic Acids - pharmacology
Carbapenem-Resistant Enterobacteriaceae - drug effects
Ceftazidime - pharmacology
Drug Combinations
Drug Resistance, Multiple, Bacterial - drug effects
Drug Resistance, Multiple, Bacterial - genetics
Experimental Therapeutics
Humans
Imipenem - pharmacology
Meropenem - pharmacology
Microbial Sensitivity Tests
Serratia Infections - microbiology
Serratia marcescens - drug effects
Serratia marcescens - genetics
Serratia marcescens - isolation & purification
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.02255-19